• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600993.SS
Share

Mayinglong Pharmaceutical Group Co., Ltd. Stocks

CN¥ 24.25Last Updated 13.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.48B

CN¥ 24.25
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, reasonably

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 18:05

June was TSMC's best month ever in terms of revenue. Is the AI rally continuing?

13.07.2026 17:31

"You Pay Twice for AI": Microsoft CEO Warns of Dependence on Anthropic and OpenAI

13.07.2026 16:55

Morgan Stanley Expects Earnings Growth Outside the Tech Sector. What to Buy Ahead of Earnings Season?

13.07.2026 16:34

Oninvest Index: Top AI Small-Caps for the First Half of the Year

13.07.2026 15:34

Morning in New York: External Factors Heighten Risks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026